A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer

INTRODUCTION: Radium-223, abiraterone, and enzalutamide have each been shown to significantly improve survival as monotherapy in patients with metastatic castration-resistant prostate cancer. However, effects of combination radium-223 plus abiraterone or enzalutamide on survival and safety remain un...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Stephanie I., Szeto, Andy H., Morgan, Katherine P., Brower, Blaine, Dunn, Mary W., Khandani, Amir H., Godley, Paul A., Rose, Tracy L., Basch, Ethan M., Milowsky, Matthew I., Whang, Young E., Crona, Daniel J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216516/
https://www.ncbi.nlm.nih.gov/pubmed/34153052
http://dx.doi.org/10.1371/journal.pone.0253021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216516/
https://www.ncbi.nlm.nih.gov/pubmed/34153052
http://dx.doi.org/10.1371/journal.pone.0253021

Ejemplares similares